|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal Susitarimą)
| (51) | INT.CL. | A61K 39/395 | |
| C07K 16/28 | |||
| A61P 35/00 | |||
| A61P 37/00 | |||
| C12N 5/20 | |||
| C07K 14/705 |
| (11) | Patento numeris | 2371391 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 10183377.0 |
| Europos patento paraiškos padavimo data | 2004-05-10 | |
| (97) | Europos patento paraiškos paskelbimo data | 2011-10-05 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2014-07-23 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (30) | Numeris | Data | Šalis |
| 469211 P | 2003-05-08 | US | |
| 557622 P | 2004-03-29 | US | |
| 557621 P | 2004-03-29 | US | |
| 557620 P | 2004-03-29 | US |
| (72) |
Williams, Marna, US
Tso, Yun J., US
Landolfi, Nicolas F., US
Liu, Gao, US
Powers, David B., US
|
| (73) |
AbbVie Biotherapeutics Inc.,
1500 Seaport Boulevard, Redwood City, CA 94063,
US
|
| (54) | Therapeutic use of anti-CS1 antibodies |
| Therapeutic use of anti-CS1 antibodies |